Advancing technology has led to the successful utilization of nextgeneration sequencing (NGS) for assessing cancer susceptibility, diagnosis, prognosis, and treatment. 
Although cancer gene panels are preferred for clinical use, since they test for select genes they may miss novel genomic alterations. Thus, unbiased strategies such as whole exome and whole transcriptome sequencing are employed in the research setting and present opportunities for discovery. 3 Since the prevalence of most actionable genomic alterations is low and occurs across tumor types, it is challenging to perform a conventional clinical trial restricted to a specific tumor type. For instance, activating mutations in ERBB2 at low frequency (<5 %) are observed across multiple cancers, including breast, colon, and lung. [12] [13] [14] Similarly, low frequency activating mutations in AKT1 (E17K) are seen across lung, breast, and biliary tumors. [15] [16] [17] Therefore, "basket trials" that enroll patients based on a specific genomic alteration (e.g., FGFR, BRAF) are being increasingly evaluated by the pharmaceutical industry and academic centers.
Recently, BRAF has been validated as an actionable alteration in certain nonmelanoma tumors through a basket trial. 18 Furthermore, the National Cancer Institute has opened National Cancer Institute-Molecular Analysis Clinical implementation of NGS has facilitated the identification of novel actionable alterations with matching targeted therapies and has revolutionized our approach to cancer care. However, lack of prolonged responses and acquired resistance with chronic treatment, intratumor heterogeneity, and issues with driver mutation interpretation have limited the overall utility. As we move forward with widespread implementation of genomics in cancer care, collaborative approach to interpretation, rational combination therapies, and serial tumor biopsies in basket trials and funding will help pave a path for precision cancer medicine. ■
